Skip to main content
. Author manuscript; available in PMC: 2013 Feb 15.
Published in final edited form as: Cancer Res. 2011 Dec 15;72(4):876–886. doi: 10.1158/0008-5472.CAN-11-1792

Figure 7. CCR2 expression on melanoma patient MDSC.

Figure 7

Healthy donor(HD) or stage III and IV melanoma patient(Pt) PBMC were evaluated by flow cytometry for the quantity of lineage negative (CD3, CD16, CD19, CD20, CD56), CD14+, HLA-DR low/neg cells (A). The expression of CCR2 was measured in comparison with isotype control in each subject (n = 3 HD, 3 Pt) (B). PBMC depleted of CCR2 expressing cells were stimulated to proliferate with OKT-3 and IL-2. CFSE dilution of CD8 T cells in the culture is shown in the absence of CCR2+ cells or with CCR2+ cells added back. The average stimulation index is graphed for 3 healthy donor and 3 melanoma patient PBMC (C). Stimulation index = (%proliferated CD8+ T cells in CCR2 depleted PBMC) ÷ (% proliferated CD8+ T cell in CCR2-PBMC with CCR2+ cell added back).